Sartorius scoops double award at Fisher Scientific European Sales Conference

4 Feb 2018

Company also promoted to Platinum supplier status in Europe.

Sartorius was a double award winner at the Fisher Scientific European Sales Conference in Malta, picking up the awards for Supplier Excellence and Best Booth. These awards coincided with the formal announcement of the promotion of Sartorius to Platinum supplier status in Europe.

Sartorius scoops double award at Fisher Scientific European Sales Conference

The Supplier Excellence Award recognized the excellent cooperation between Fisher Scientific and Sartorius. The year 2017 saw the Sartorius business with Fisher Scientific increase. The award also recognizes Sartorius for supply chain excellence, product quality and marketing support. The Best Booth award, which is voted for by the Fisher Scientific Commercial team, is awarded to the supplier whose booth best incorporates the four values of Fisher Scientific: involvement, intensity, innovation and integrity.

John Collings, European Category Director at Fisher Scientific, announced the change in partnership and explained what it means for the relationship between the two companies. “This change is a significant long-term investment from both companies and will now help us move forward in strategic partnership. This promotion to Platinum will also drive ambitious revenue growth targets, through increased marketing, commercial, supply chain and strategic plans.”

Daniela Winzker-Demes, Sartorius’ Vice President of LPS Sales & Services EMEA, and John Bryson, Director Channel Management Europe, proudly accepted the awards. “The new status is an incentive for us to intensify our cooperation to continuously improve our customers’ experience," said Winzker-Demes. John Bryson commented: “These awards, and the move to Platinum status, reflect our shared success and close partnership with Fisher Scientific. We look forward to another successful year in 2018 as we work together to drive further growth and deliver solutions to our customers.”

Read More

Related tags

Market News

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more